Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-101 versus Stalevo in Parkinson's disease with end-of-dose motor fluctuations
2010-022200-46Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ODM-101 in Parkinson's disease (PD) (2 arms), sponsored by Orion Corporation. Primary endpoint: Motor status by patient diary. Started Mar 2011; status: completed.
02
Drugs
ODM-101
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2010-022200-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022200-46.